Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
In November, NVO shares crossed into a long-term bear market as they fell below their 20-month moving average - a key ...
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados ...
1don MSN
Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.
Stocks traded sharply higher Friday as a key inflation measure came in lower than expected. The Dow Jones Industrial Average ...
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback